Leica biosystems
Idecabtagene vicleucel in relapsed and refractory multiple myeloma. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. B-cell maturation antigen is exclusively expressed in a wide range of B-cell and plasma cell neoplasm and in a potential therapeutic target for BCMA directed therapies. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Emerging immunotherapies in multiple myeloma. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Shah, N., Chari, A., Scott, E., Mezzi, K. SOHO state of the art updates and next questions: T-cell-directed immune therapies for multiple myeloma: chimeric antigen receptor-modified T cells and bispecific T-cell-engaging agents. Source data are provided with this paper. 1, 2, 6 and 9d–f), source data are available. For all clinical measurements and cytokine levels (Extended Data Figs. Specific URLs to recreate the following figures are provided: Fig. The images derived from the Allen Human Brain Atlas can be accessed at. Mass cytometry and intracellular cytokine data are available through the FlowRepository website (ID FR-FCM-Z4KB). Raw and analyzed CITE-seq data are available through the National Center for Biotechnology Information’s Gene Expression Omnibus (accession no. Any data and materials that can be shared will be released via a material transfer agreement. Requests for data should be addressed to the corresponding author via e-mail, and a reply will be sent within ten business days.
#LEICA BIOSYSTEMS TRIAL#
Given reports of three patients with grade 3 or higher parkinsonism on the phase 2 ciltacabtagene autoleucel trial and of grade 3 parkinsonism in the idecabtagene vicleucel package insert, our findings support close neurological monitoring of patients on BCMA-targeted T cell therapies.Īll requests for raw and analyzed data and materials will be promptly reviewed by the Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital to determine if the request is subject to any confidentiality and data protection obligations. Public transcriptomic datasets further confirm BCMA RNA expression in the caudate of normal human brains, suggesting that this might be an on-target effect of anti-BCMA therapy. We show BCMA expression on neurons and astrocytes in the patient’s basal ganglia. Here, we describe the case of a patient with MM who was enrolled in the CARTITUDE-1 trial ( NCT03548207) and who developed a progressive movement disorder with features of parkinsonism approximately 3 months after ciltacabtagene autoleucel BCMA-targeted CAR-T cell infusion, associated with CAR-T cell persistence in the blood and cerebrospinal fluid, and basal ganglia lymphocytic infiltration. B-cell maturation antigen (BCMA) is a prominent tumor-associated target for chimeric antigen receptor (CAR)-T cell therapy in multiple myeloma (MM).